BIO3 Share Price

Open 20.99 Change Price %
High 21.20 1 Day -2.40 -10.57
Low 19.89 1 Week 0.00 0.00
Close 20.30 1 Month -1.45 -6.67
Volume 147821 1 Year 6.37 45.73
52 Week High 23.88
52 Week Low 12.79
BIO3 Important Levels
Resistance 2 21.51
Resistance 1 21.01
Pivot 20.46
Support 1 19.59
Support 2 19.09
ETR Germany Most Active Stocks
DTE 15.31 -2.11%
DTE 15.31 -2.11%
DTE 15.31 -2.11%
DTE 15.31 -2.11%
DTE 15.31 -2.11%
DBK 14.13 1.29%
DBK 14.13 1.29%
EOAN 10.38 2.47%
EOAN 10.38 2.47%
CBK 11.88 0.93%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
M3B 0.84 21.74%
CR8 7.33 20.16%
R3Q 0.12 20.00%
5M71 39.00 13.70%
WI4 1.12 13.13%
KU2 210.50 11.97%
SONA 35.85 11.75%
SONA 35.85 11.75%
ELG 27.09 11.53%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
U9R 10.60 -24.56%
BIO 24.70 -11.41%
BIO 24.70 -11.41%
BIO 24.70 -11.41%
BIO 24.70 -11.41%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 2
As on 1st Nov 2017 BIO3 Share Price closed @ 20.30 and we RECOMMEND Buy for LONG-TERM with Stoploss of 19.56 & Strong Sell for SHORT-TERM with Stoploss of 22.83 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for November
1st Target up-side 23.84
2nd Target up-side 24.65
3rd Target up-side 25.45
1st Target down-side 21.56
2nd Target down-side 20.75
3rd Target down-side 19.95
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.